JP2016515526A - 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 - Google Patents
酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 Download PDFInfo
- Publication number
- JP2016515526A JP2016515526A JP2016503224A JP2016503224A JP2016515526A JP 2016515526 A JP2016515526 A JP 2016515526A JP 2016503224 A JP2016503224 A JP 2016503224A JP 2016503224 A JP2016503224 A JP 2016503224A JP 2016515526 A JP2016515526 A JP 2016515526A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- oxidative stress
- group
- alkyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *c1nc(ccc(F)c2)c2[n]1 Chemical compound *c1nc(ccc(F)c2)c2[n]1 0.000 description 11
- PUDPUBVCQGDVLT-UHFFFAOYSA-N CC(C(C(C)=C1CCCc([nH]2)nc3c2nccc3)=O)=C(C)C1=O Chemical compound CC(C(C(C)=C1CCCc([nH]2)nc3c2nccc3)=O)=C(C)C1=O PUDPUBVCQGDVLT-UHFFFAOYSA-N 0.000 description 1
- CPROENOMYBEKDS-UHFFFAOYSA-N CC(C(C(C)=C1CCCc2nc(cc(cc3)F)c3[nH]2)=O)=C(C)C1=O Chemical compound CC(C(C(C)=C1CCCc2nc(cc(cc3)F)c3[nH]2)=O)=C(C)C1=O CPROENOMYBEKDS-UHFFFAOYSA-N 0.000 description 1
- IEYMMOJYBDUIQT-UHFFFAOYSA-N CC(C(C(C)=C1CCCc2nc(ccc(C(N)=O)c3)c3[nH]2)=O)=C(C)C1=O Chemical compound CC(C(C(C)=C1CCCc2nc(ccc(C(N)=O)c3)c3[nH]2)=O)=C(C)C1=O IEYMMOJYBDUIQT-UHFFFAOYSA-N 0.000 description 1
- HFFNXSWRRGQZHG-UHFFFAOYSA-N CC(C(C(C)=C1CCCc2nc(ccc(C(N3CCN(C)CC3)=O)c3)c3[nH]2)=O)=C(C)C1=O Chemical compound CC(C(C(C)=C1CCCc2nc(ccc(C(N3CCN(C)CC3)=O)c3)c3[nH]2)=O)=C(C)C1=O HFFNXSWRRGQZHG-UHFFFAOYSA-N 0.000 description 1
- PHHVWWFTLFCUHJ-UHFFFAOYSA-N CC(C(C(C)=C1CCCc2nc(cccc3)c3[s]2)=O)=C(C)C1=O Chemical compound CC(C(C(C)=C1CCCc2nc(cccc3)c3[s]2)=O)=C(C)C1=O PHHVWWFTLFCUHJ-UHFFFAOYSA-N 0.000 description 1
- OCOOYIYVLKQMDT-UHFFFAOYSA-N CC(C(C(C)=C1CCCc2nc3ccccc3[n]2C)=O)=C(C)C1=O Chemical compound CC(C(C(C)=C1CCCc2nc3ccccc3[n]2C)=O)=C(C)C1=O OCOOYIYVLKQMDT-UHFFFAOYSA-N 0.000 description 1
- XFCSFMWJRASOFQ-UHFFFAOYSA-N CC(C(C(C)=C1CCCc2nc3ccccc3[o]2)=O)=C(C)C1=O Chemical compound CC(C(C(C)=C1CCCc2nc3ccccc3[o]2)=O)=C(C)C1=O XFCSFMWJRASOFQ-UHFFFAOYSA-N 0.000 description 1
- ZHZZLLYMPREAKJ-UHFFFAOYSA-N CC(C(C(C)=C1C[n]2cncc2)=O)=C(C)C1=O Chemical compound CC(C(C(C)=C1C[n]2cncc2)=O)=C(C)C1=O ZHZZLLYMPREAKJ-UHFFFAOYSA-N 0.000 description 1
- IPGAFOVEIIWXFR-UHFFFAOYSA-N CC(C(C(C)=C1Cc2cnccc2)=O)=C(C)C1=O Chemical compound CC(C(C(C)=C1Cc2cnccc2)=O)=C(C)C1=O IPGAFOVEIIWXFR-UHFFFAOYSA-N 0.000 description 1
- AWQQDKNKCFOJAC-UHFFFAOYSA-N CC(C(C(OC)=C1OC)=O)=C(Cc2cnccc2)C1=O Chemical compound CC(C(C(OC)=C1OC)=O)=C(Cc2cnccc2)C1=O AWQQDKNKCFOJAC-UHFFFAOYSA-N 0.000 description 1
- DFIDLWGMNMGWKW-UHFFFAOYSA-N CC(C(CCCc1nc(ccc(F)c2)c2[nH]1)C(C(C)=C1C)=O)C1=O Chemical compound CC(C(CCCc1nc(ccc(F)c2)c2[nH]1)C(C(C)=C1C)=O)C1=O DFIDLWGMNMGWKW-UHFFFAOYSA-N 0.000 description 1
- GTHYMXFSZNIPNL-UHFFFAOYSA-N CCc1nc(cc(C(F)(F)F)cc2)c2[s]1 Chemical compound CCc1nc(cc(C(F)(F)F)cc2)c2[s]1 GTHYMXFSZNIPNL-UHFFFAOYSA-N 0.000 description 1
- JAWXWPPUMGPAAP-UHFFFAOYSA-N Cc(c(C)c(c(CCCC(O)=O)c1C)OC)c1OC Chemical compound Cc(c(C)c(c(CCCC(O)=O)c1C)OC)c1OC JAWXWPPUMGPAAP-UHFFFAOYSA-N 0.000 description 1
- BDXHKUUYEDEAJB-UHFFFAOYSA-N Cc(c(C)c(c(Cc1cnccc1)c1C)O)c1O Chemical compound Cc(c(C)c(c(Cc1cnccc1)c1C)O)c1O BDXHKUUYEDEAJB-UHFFFAOYSA-N 0.000 description 1
- WGJULIBRKGIOAR-UHFFFAOYSA-N Cc(c(Cc1cnccc1)c(c(OC)c1OC)O)c1O Chemical compound Cc(c(Cc1cnccc1)c(c(OC)c1OC)O)c1O WGJULIBRKGIOAR-UHFFFAOYSA-N 0.000 description 1
- DUMFHTNODSNNJM-UHFFFAOYSA-N Cc1c(C)c(O)c(C[n]2cncc2)c(C)c1O Chemical compound Cc1c(C)c(O)c(C[n]2cncc2)c(C)c1O DUMFHTNODSNNJM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798937P | 2013-03-15 | 2013-03-15 | |
| US61/798,937 | 2013-03-15 | ||
| PCT/US2014/029806 WO2014145116A2 (en) | 2013-03-15 | 2014-03-14 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016515526A true JP2016515526A (ja) | 2016-05-30 |
| JP2016515526A5 JP2016515526A5 (enExample) | 2017-04-20 |
Family
ID=50588910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503224A Ceased JP2016515526A (ja) | 2013-03-15 | 2014-03-14 | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10189830B2 (enExample) |
| EP (1) | EP2970158B1 (enExample) |
| JP (1) | JP2016515526A (enExample) |
| CA (1) | CA2906145A1 (enExample) |
| HK (1) | HK1220451A1 (enExample) |
| WO (1) | WO2014145116A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022551270A (ja) * | 2019-10-04 | 2022-12-08 | ステルス バイオセラピューティクス インコーポレイテッド | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2564843B1 (en) | 2005-06-01 | 2018-12-26 | Bioelectron Technology Corporation | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| DK2220030T3 (en) | 2007-11-06 | 2016-04-11 | Edison Pharmaceuticals Inc | 4- (P-QUINONYL) -2-HYDROXYBUTANAMIDDERIVATER TO TREAT mitochondrial |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| EP2892516A1 (en) | 2012-09-07 | 2015-07-15 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| PL3233786T3 (pl) | 2014-12-16 | 2022-06-13 | Ptc Therapeutics, Inc. | Polimorficzne i amorficzne postacie (r)-2-hydroksy-2-metylo-4-(2,4,5-trimetylo-3,6-dioksocykloheksa-1,4-dienylo)butanoamidu |
| EP3390377A1 (en) | 2015-12-16 | 2018-10-24 | BioElectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| BR112021007153A2 (pt) | 2018-10-17 | 2021-07-20 | Ptc Therapeutics, Inc. | 2,3,5-trimetil-6-nonilcicloexa-2,5-dieno-1,4-diona para a supressão e tratamento de a-sinucleinopatias, tauopatias e outros distúrbios |
| WO2021202986A1 (en) | 2020-04-03 | 2021-10-07 | Stealth Biotherapeutics Corp | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia |
| WO2023283466A1 (en) | 2021-07-08 | 2023-01-12 | Ptc Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62223150A (ja) * | 1986-02-12 | 1987-10-01 | Otsuka Pharmaceut Co Ltd | １，４−ベンゾキノン誘導体 |
| JPS6345257A (ja) * | 1986-01-30 | 1988-02-26 | Takeda Chem Ind Ltd | キノン誘導体 |
| JPH04225972A (ja) * | 1990-05-11 | 1992-08-14 | Suntory Ltd | ベンゾフラン誘導体及びそれを含む虚血による器質性又は機能性障害治療剤 |
| JPH0959258A (ja) * | 1995-08-11 | 1997-03-04 | Ono Pharmaceut Co Ltd | グアニジル誘導体 |
| JP2011503005A (ja) * | 2007-11-06 | 2011-01-27 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病を治療するための４−（ｐ−キノリル）−２−ヒドロキシブタンアミド誘導体 |
| JP2011513423A (ja) * | 2008-03-05 | 2011-04-28 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体 |
| JP2011525926A (ja) * | 2008-06-25 | 2011-09-29 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 |
| JP2012500260A (ja) * | 2008-08-18 | 2012-01-05 | イェール・ユニヴァーシティー | Ｍｉｆモジュレーター |
| WO2012022467A2 (en) * | 2010-08-16 | 2012-02-23 | Santhera Pharmaceuticals (Schweiz) Ag | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229385A (en) * | 1986-01-30 | 1993-07-20 | Takeda Chemical Industries, Ltd. | Quinone derivatives, their production and use |
| EP0560568A3 (en) | 1992-03-13 | 1994-06-29 | Takeda Chemical Industries Ltd | Hydroquinone derivatives and intermediates for production thereof |
| CA2196426A1 (en) | 1994-08-12 | 1996-02-22 | Shinji Terao | Use of quinone and hydroquinone derivatives for the teatment of cachexia |
| CA2224517A1 (en) | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
| JPH09221471A (ja) | 1995-12-15 | 1997-08-26 | Takeda Chem Ind Ltd | キノン誘導体の製造法および中間体 |
| WO1997029776A1 (en) | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors |
| US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| DE10121252A1 (de) | 2001-04-30 | 2002-11-07 | Christos C Zouboulis | Behandlung der Akne |
| NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
| GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
| DE60211875T2 (de) | 2002-07-01 | 2006-10-26 | Santhera Pharmaceuticals (Schweiz) Ag | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia |
| AU2003287250B9 (en) | 2002-10-30 | 2010-01-28 | Ptc Therapeutics, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
| US7470798B2 (en) | 2003-09-19 | 2008-12-30 | Edison Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| US7067659B2 (en) | 2004-04-23 | 2006-06-27 | Duke University | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof |
| MX2007010721A (es) | 2005-03-01 | 2007-11-13 | Pfizer Ltd | Nuevo uso de inhibidores de fosfodiesterasa 7 para el tratamiento de dolor neuropatico. |
| EP2564843B1 (en) | 2005-06-01 | 2018-12-26 | Bioelectron Technology Corporation | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP1947942B1 (en) | 2005-08-18 | 2015-07-29 | Accelalox, Inc. | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway |
| LT1933821T (lt) | 2005-09-15 | 2020-11-10 | Ptc Therapeutics, Inc. | Šoninės grandinės variantai redoks aktyviųjų terapijos priemonių, skirtų mitochondrinių ligų ir kitokių būklių gydymui ir energijos biologinių žymenų moduliavimui |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| WO2009105723A2 (en) | 2008-02-22 | 2009-08-27 | Accelalox, Inc. | Novel methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway |
| CA2717741C (en) | 2008-03-05 | 2018-04-03 | Edison Pharmaceuticals, Inc. | Treatment of hearing and balance impairments with redox-active therapeutics |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| US20100273892A1 (en) | 2009-04-28 | 2010-10-28 | Miller Guy M | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases |
| HUE037592T2 (hu) | 2009-08-26 | 2018-09-28 | Bioelectron Tech Corp | Eljárások cerebrális ischemia megelõzésére és kezelésére |
| EP2519232A1 (en) | 2009-12-31 | 2012-11-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| AU2011245384C1 (en) | 2010-04-27 | 2016-09-01 | Bioelectron Technology Corporation | Formulations of quinones for the treatment of ophthalmic diseases |
| US20130345312A1 (en) | 2010-08-06 | 2013-12-26 | Orion D. Jankowski | Treatment of mitochondrial diseases with naphthoquinones |
| US20120076795A1 (en) | 2010-09-27 | 2012-03-29 | Sutter West Bay Hospitals D/B/A California Pacific Medical Center | Anti-PECAM Therapy, Compositions, Methods, and Uses |
| US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013006737A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc. | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| RS56226B1 (sr) | 2012-03-14 | 2017-11-30 | Levicept Ltd | P75ntr neurotrofin vezujući protein za terapijsku primenu |
| WO2014031586A2 (en) | 2012-08-20 | 2014-02-27 | Tallikut Pharmaceuticals, Inc. | Methods for treating cardiovascular diseases |
| EP2892516A1 (en) | 2012-09-07 | 2015-07-15 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| HK1223369A1 (zh) | 2013-05-31 | 2017-07-28 | Bioelectron Technology Corporation | 用於治疗氧化应激障碍的羧酸衍生物 |
-
2014
- 2014-03-14 EP EP14720006.7A patent/EP2970158B1/en not_active Not-in-force
- 2014-03-14 JP JP2016503224A patent/JP2016515526A/ja not_active Ceased
- 2014-03-14 HK HK16108427.8A patent/HK1220451A1/zh unknown
- 2014-03-14 CA CA2906145A patent/CA2906145A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/029806 patent/WO2014145116A2/en not_active Ceased
- 2014-03-14 US US14/776,678 patent/US10189830B2/en not_active Expired - Fee Related
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6345257A (ja) * | 1986-01-30 | 1988-02-26 | Takeda Chem Ind Ltd | キノン誘導体 |
| JPS62223150A (ja) * | 1986-02-12 | 1987-10-01 | Otsuka Pharmaceut Co Ltd | １，４−ベンゾキノン誘導体 |
| JPH04225972A (ja) * | 1990-05-11 | 1992-08-14 | Suntory Ltd | ベンゾフラン誘導体及びそれを含む虚血による器質性又は機能性障害治療剤 |
| JPH0959258A (ja) * | 1995-08-11 | 1997-03-04 | Ono Pharmaceut Co Ltd | グアニジル誘導体 |
| JP2011503005A (ja) * | 2007-11-06 | 2011-01-27 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病を治療するための４−（ｐ−キノリル）−２−ヒドロキシブタンアミド誘導体 |
| JP2011513423A (ja) * | 2008-03-05 | 2011-04-28 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体 |
| JP2011525926A (ja) * | 2008-06-25 | 2011-09-29 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 |
| JP2012500260A (ja) * | 2008-08-18 | 2012-01-05 | イェール・ユニヴァーシティー | Ｍｉｆモジュレーター |
| WO2012022467A2 (en) * | 2010-08-16 | 2012-02-23 | Santhera Pharmaceuticals (Schweiz) Ag | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
Non-Patent Citations (5)
| Title |
|---|
| ANDREANI, A. ET AL.: "Effects of new ubiquinone-imidazo[2,1-b]thiazoles on mitochondrial complex I (NADH-ubiquinone reduct", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12(21), JPN6018002281, 2004, pages 5525 - 5532, ISSN: 0003928719 * |
| OHKAWA, S. ET AL.: "Reduction of 2,3,5-Trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone by PB-3c Cells and Biological Acti", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 39(4), JPN6018002282, 1991, pages 917 - 921, ISSN: 0003928721 * |
| REGISTRY（STN）[ONLINE], vol. Entered STN: 08 Jun 2008, JPN7018000206, pages 2017 - 12, ISSN: 0003928720 * |
| REGISTRY（STN）[ONLINE], vol. Entered STN: 19 Sep 2004, JPN7018000207, pages 2017 - 12, ISSN: 0003928722 * |
| SUZUKI, K. ET AL.: "2-Arylmethyl-1,4-benzoquinones. II. Novel Inhibitors of Platelet Aggregation: Synthesis and Pharmaco", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 45(4), JPN6018002279, 1997, pages 668 - 674, ISSN: 0003928718 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022551270A (ja) * | 2019-10-04 | 2022-12-08 | ステルス バイオセラピューティクス インコーポレイテッド | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1220451A1 (zh) | 2017-05-05 |
| WO2014145116A3 (en) | 2015-01-15 |
| US10189830B2 (en) | 2019-01-29 |
| EP2970158A2 (en) | 2016-01-20 |
| US20160024085A1 (en) | 2016-01-28 |
| EP2970158B1 (en) | 2019-02-20 |
| WO2014145116A2 (en) | 2014-09-18 |
| CA2906145A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515526A (ja) | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 | |
| JP5798481B2 (ja) | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 | |
| US9629815B2 (en) | Benzoquinone derivatives for treating oxidative stress disorders | |
| US9296712B2 (en) | Resorufin derivatives for treatment of oxidative stress disorders | |
| JP2016520621A (ja) | 酸化ストレス障害の処置のためのカルボン酸誘導体 | |
| JP2016514697A (ja) | 酸化ストレス障害の処置のためのフェナジン−３−オンおよびフェノチアジン−３−オン誘導体 | |
| US9868711B2 (en) | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders | |
| US9090576B2 (en) | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | |
| US9670170B2 (en) | Resorufin derivatives for treatment of oxidative stress disorders | |
| RU2770091C2 (ru) | Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида | |
| WO2010014758A1 (en) | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress | |
| HK1236924A1 (en) | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide | |
| HK1236924B (en) | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170314 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170314 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180424 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180622 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180725 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180725 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190228 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190322 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20190724 |